EMR 100070-004 – A phase III open-label, multicenter trial of MSB0010718C
versus Docetaxel in subjects with non-small cell lung cancer that has
progressed after a platinum-containing doublet.
What type of cancer? What stage?
2nd line lung has opened
Who is eligible?
How will I be treated?
MSB0010718C-PDL1-Avelumab
SWOG 1400
SWOG 1400 – Phase II/III biomarker-driven master protocol for second
line therapy of squamous cell lung cancer.
What type of cancer? What stage?
Lung cancer.
Who is eligible?
Patients who need 2nd line therapy of squamous cell lung cancer.
How will I be treated?
Patients will have therapies directed by tumor genetics.
E4512
E4512 – A phase III double-blinded trial for surgically early stage
non-small cell lung cancer: crizotinib versus placebo for patients with
tumors harboring the anaplastic lymphoma kinase (ALK) fusion protein.
What type of cancer? What stage?
Lung cancer, surgically removed.
Who is eligible?
Patients who have an ALK mutation.
How will I be treated?
Patients may get Crizonitib (a drug approved for ALK+ lung cancer).
A081105
A081105 – Randomized double blind placebo controlled study of Erlotinib
or placebo in patients with completely resected epidermal growth factor
receptor (EGFR) mutant non-small
What type of cancer? What stage?
Lung cancer.
Who is eligible?
EGFR mutant non-small cell lung cancer.
How will I be treated?
Erlotinib (anti-body based biologic).
A151216
A151216 – Genetic testing for patients with resectable or resected
lung cancer: adjuvant lung cancer enrichment marker identification and
sequencing trial (alchemist).
What type of cancer? What stage?
Lung cancer.
Who is eligible?
Patients whose disease is resected (surgically removed).
How will I be treated?
Genetic testing will be incorporated to learn more about tumor biology.
For physicians: more information about this specific trial at
clinicaltrials.gov.
